FDA lifts clinical hold on Repros' Proellex

06/13/2010 | Bloomberg Businessweek

The FDA approved Repros Therapeutics' request to conduct another trial of Proellex for use in reducing menstrual bleeding associated with uterine fibroids and endometriosis, lifting a clinical hold that was placed on the drug candidate last year because of liver toxicity. The drugmaker will test lower doses of Proellex on 12 women in a 10-week study comparing the drug with placebo.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA